Genetic Modulation of Lipid-Associated Disability Progression in Multiple Sclerosis
Multiple sclerosis (MS) is a complex neurological disease in which inflammatory demyelination, axonal injury and neurodegeneration collectively contribute to accumulating disability. Although substantial progress has been made in identifying genetic and environmental determinants of MS susceptibility, the biological factors governing the rate of disability progression remain less clearly defined. The study by Zhang and colleagues, entitled “Lipid-related genetic polymorphisms significantly modulate the association between lipids and disability progression in multiple sclerosis,” addresses this knowledge gap by examining whether common genetic variants associated with lipid metabolism or body mass index modify the clinical course of MS. The central premise is that lipid concentrations should not be interpreted solely as metabolic measurements: their neurological consequences may depend partly on inherited genetic architecture. This approach is particularly relevant because previous studies have associated higher total cholesterol, low-density lipoprotein cholesterol and total cholesterol-to-high-density lipoprotein ratios with greater disability, whereas higher high-density lipoprotein levels have generally been associated with more favourable outcomes.
Longitudinal Cohort Design and Analytical Framework
The investigators analysed 184 participants with confirmed MS from the Ausimmune Longitudinal Study, a prospective cohort established to investigate determinants of early MS progression. Participants had genome-wide genotyping data and Expanded Disability Status Scale measurements available at baseline and at approximately five years. Annualised disability progression was calculated as the change in EDSS divided by the relevant follow-up duration, generating the outcome variable ΔEDSS. Baseline serum measurements included total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol and triglycerides, while non-HDL cholesterol and the total cholesterol-to-HDL ratio were calculated from these values. The genetic analysis considered 162 lipid-associated single-nucleotide polymorphisms and 97 BMI-associated polymorphisms identified through previous genome-wide association studies. Linear regression models were adjusted for age, sex, study site and relapse status at the five-year disability assessment, while permutation testing and correction for multiple comparisons were applied to evaluate the robustness of the observed associations.
Individual Variants and the Cumulative Genetic Risk Score
Five lipid-related polymorphisms—rs2013208, rs9488822, rs17173637, rs10401969 and rs2277862—were nominally associated with annualised EDSS change. These variants were located within or near the genes RBM5, FRK, TMEM176A, CILP2 and ERGIC3, respectively. Nevertheless, none remained statistically significant after stringent correction for the large number of comparisons, an important qualification when interpreting individual variant effects. The investigators subsequently combined the five variants into a cumulative genetic risk score, thereby testing their aggregate contribution rather than treating each polymorphism as an isolated predictor. This score demonstrated a pronounced dose-dependent relationship with disability progression. Participants carrying three or fewer risk alleles had an annualised EDSS change of approximately 0.21 points, whereas those carrying six or more risk alleles progressed an additional 0.38 EDSS points per year. The trend was highly significant, and the cumulative score accounted for approximately 16% of the variance in annualised disability progression after covariate adjustment.
Genetic Risk Modifies the Effect of the Lipid Profile
The most consequential finding was not merely that lipid-related variants were associated with progression, but that genetic risk altered the relationship between serum lipids and disability. Significant interactions were detected between the cumulative genetic risk score and both HDL cholesterol and the total cholesterol-to-HDL ratio. Among participants with four or fewer risk alleles, disability progression showed little variation across HDL concentrations or cholesterol ratios. By contrast, participants with more than four risk alleles experienced substantially faster progression when HDL levels were lower or when the total cholesterol-to-HDL ratio was higher. This pattern is illustrated in Figure 1 on page 4, where the progression curves diverge according to genetic risk burden: the high-risk group displays an inverse association between HDL and ΔEDSS and a positive association between the total cholesterol-to-HDL ratio and ΔEDSS. Incorporating genetic and lipid information increased the proportion of explained disability variance to 26% for HDL and 27% for the cholesterol ratio, compared with substantially lower values for lipid variables alone.
Potential Biological Interpretation
These results support a model in which lipid metabolism and genetic susceptibility converge to influence neurological damage. An adverse lipid profile may contribute to endothelial dysfunction, vascular comorbidity, oxidative stress, inflammatory signalling or altered membrane and myelin homeostasis. However, the direction of effect was not uniform across all five variants. For example, rs9488822 was associated with higher cholesterol and faster disability progression, which is biologically consistent with the proposed adverse effect of dyslipidaemia. In contrast, rs2277862 was associated with lower total cholesterol but greater progression, suggesting that the implicated variants may exert pleiotropic effects that are not mediated exclusively through circulating lipid concentrations. Several nearby genes also have potential neurological or immunological relevance. RBM5 has been linked to aberrant RNA regulation, TMEM176A is reportedly upregulated in blood samples from people with MS, and the BMI-associated variant rs2033529 lies near LRFN2, a gene implicated in neuronal process regeneration. Functional studies are therefore required to determine whether these loci influence progression through lipid pathways, immune regulation, neurodegeneration or multiple mechanisms simultaneously.
Scientific Strengths and Methodological Limitations
A major strength of the investigation is its longitudinal design, which allowed the authors to evaluate clinically meaningful disability change over approximately five years rather than relying on cross-sectional disease severity. Lipid measurements were collected before the progression outcome was determined, and inherited genetic variants are not altered by subsequent disability, reducing the likelihood of reverse causation. The study also incorporated dose-response assessment, permutation testing, cumulative risk modelling and formal interaction analyses. Nevertheless, the sample size of 184 participants remains modest for genetic epidemiology, particularly when hundreds of polymorphisms are examined. None of the five lipid-associated variants survived correction for multiple testing, and the subgroup carrying six or more risk alleles contained only 14 individuals. The cumulative score was also derived and evaluated within the same cohort, raising the possibility of model overfitting. Furthermore, EDSS is weighted strongly toward ambulatory function and may not fully represent cognitive impairment, fatigue or upper-limb disability. The authors appropriately emphasise that both false-positive and false-negative findings remain possible and that independent replication is essential.
Implications for Precision Medicine and Future Research
The study provides preliminary evidence that lipid management in MS may eventually require a stratified rather than uniform therapeutic approach. Interventions that improve HDL levels or reduce an adverse total cholesterol-to-HDL ratio may offer greater neurological benefit in patients carrying particular lipid-related risk alleles. Such a hypothesis could help explain why clinical trials of statins in MS have produced inconsistent results: treatment effects may be diluted when genetically responsive and non-responsive participants are analysed together. However, the present findings do not establish that statins or other lipid-modifying interventions prevent MS progression, nor do they justify clinical genetic testing based on these five variants. The immediate priorities are replication in larger and ethnically diverse cohorts, construction of externally validated polygenic scores, integration with magnetic-resonance imaging and molecular biomarkers, and mechanistic investigation of the implicated genes. The study’s broader contribution is conceptual: it demonstrates that metabolic exposures and inherited variation may operate jointly, with their combination explaining more than one-quarter of disability variation in this cohort.
Disclaimer: This blog post is based on the provided research article and is intended for informational purposes only. It is not intended to provide medical advice. Please consult with a healthcare professional for any health concerns.
References:
Zhang, Y., Zhou, Y., Van Der Mei, I. A., Simpson, S., Ponsonby, A. L., Lucas, R. M., ... & Ausimmune/AusLong Investigators Group. (2019). Lipid-related genetic polymorphisms significantly modulate the association between lipids and disability progression in multiple sclerosis. Journal of Neurology, Neurosurgery & Psychiatry, 90(6), 636-641.
